The Twin Vulnerabilities Behind India's Export Boom

India’s exports are booming, but heavy import dependence, especially on China, raises a question: how much value stays at home?

Article related image
istock.com
Author
By Ritesh Kumar Singh

Ritesh Kumar Singh is a business economist and CEO of Indonomics Consulting.

November 20, 2026 at 12:04 PM IST

India's merchandise exports rose 22.0% to $309.06 billion during the first seven months of the current fiscal.

The expansion was broad-based, with seven of the ten leading export categories recording double-digit growth. Exports of electronic goods rose 46.9%, petroleum products 47.7%, engineering goods 22%, and organic and inorganic chemicals 18.2%. A weaker rupee may have supported exporters’ competitiveness, while these numbers reflect the growing ability of Indian manufacturers to tap overseas markets.

A striking feature of India's export growth is that many industries recording strong export growth are also highly import-intensive, with significant dependence on China in several cases. 

This raises an important question: how much of the export growth translates into domestic value addition, and how resilient are the supply chains supporting it?

High import intensity limits the domestic value addition from export growth. The vulnerability is even greater when manufacturers rely on a concentrated group of overseas suppliers for critical components, intermediate goods and raw materials. In India's case, this is particularly relevant because China, a strategic rival, is a major supplier to several important manufacturing industries.

Petroleum products offer a useful contrast. Exports of petroleum products have risen sharply, while the refining industry depends heavily on imported crude oil. However, India’s crude oil sourcing is diversified across suppliers. The situation is different in electronics and pharmaceuticals, where dependence on China is very high. This distinction matters: import dependence does not necessarily translate into supply-chain vulnerability of the same magnitude when alternative sources are available.

India's growing electronics exports have not been matched by a comparably developed domestic component ecosystem, while dependence on China has increased over the past few years. A study by the Koan Advisory Group and the Institute of Chinese Studies found that China supplied at least 80% of India's imports across 71 electronics product lines in 2025-26, up from 44 product lines in 2018-19. These include components used in telecom infrastructure and consumer electronics. China also accounted for 83.6% of India's lithium-ion battery imports and 48.9% of semiconductor imports in 2025-26.

The distinction between assembling a product and manufacturing its components is important. India's growing smartphone exports are a sign of progress, but the extent to which this translates into domestic value addition depends on how much of the supply chain is located within the country. When critical components are imported, a significant share of the value embodied in exported products goes to suppliers elsewhere. Concentrated sourcing also leaves manufacturers exposed to export controls and price swings.

The pharmaceutical industry presents a similar picture. India is one of the world's largest suppliers of generic medicines, with a strong presence in international markets. Yet its manufacturing ecosystem remains heavily dependent on imported active pharmaceutical ingredients, key starting materials,  and drug intermediates. China's accounted for 73.7% of India's imports of these inputs in  2024-25. The dependence is even more pronounced in antibiotics, where China accounted for 86.1% of India's imports in the category, according to NITI Aayog.

The dependence extends beyond APIs themselves. Even when Indian manufacturers produce APIs domestically, they often rely on imported key starting materials, which are essential building blocks in the manufacturing process. For instance, key starting materials for drugs such as azithromycin, ciprofloxacin, and cephalosporins are primarily sourced from China. This means that India's strength in finished pharmaceutical formulations has not been matched by comparable capabilities across the upstream supply chain. The availability and cost of some essential inputs therefore remain closely tied to Chinese suppliers, creating risks of supply disruptions and price volatility.

None of this means that imports are inherently undesirable or that every imported component is used in goods meant for export. Access to competitively priced inputs is an integral part of modern manufacturing and can make Indian exports more competitive. 

The real concern is the combination of high import intensity and concentrated sourcing of critical inputs, which can leave manufacturers vulnerable even as their exports expand.

Nor can this dependence be addressed simply by restricting imports. Domestic manufacturers need access to technology, capital, scale, and specialised skills to produce components and intermediates competitively. The policy focus should be on building these capabilities, encouraging investment in upstream manufacturing and diversifying sourcing where domestic production is not yet viable.

India's export performance deserves recognition. But export growth alone is not enough to establish the strength of its manufacturing base. The real test is whether the country can capture a greater share of the value embodied in its exports while reducing its vulnerability to concentrated overseas supply chains. 

The next phase of India's export strategy must therefore look beyond the value of goods shipped overseas to the domestic capabilities that make those exports possible.